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Passive immunization against-amyloid (A) has become an increasingly desirable strategy as a therapeutic treatment for Alzheimer’s
disease (AD). However, traditional passive immunization approaches carry the risk of Fc receptor-mediated overactivation of micro-
glial cells, which may contribute to an inappropriate proinflammatory response leading to vasogenic edema and cerebral microhemor-
rhage.Here,wedescribe the generationof ahumanizedanti-Amonoclonal antibodyof an IgG4 isotype, knownasMABT5102A (MABT).
An IgG4 subclass was selected to reduce the risk of Fc receptor-mediated overactivation ofmicroglia.MABTboundwith high affinity to
multiple forms of A, protected against A1–42 oligomer-induced cytotoxicity, and increased uptake of neurotoxic A oligomers by
microglia. Furthermore, MABT-mediated amyloid plaque removal was demonstrated using in vivo live imaging in hAPP(V717I)/PS1
transgenicmice.Whencomparedwith ahuman IgG1wild-type subclass, containing the sameantigen-binding variable domains andwith
equal binding toA,MABTshowed reduced activationof stress-activatedp38MAPK(p38mitogen-activatedprotein kinase) inmicroglia
and induced less release of the proinflammatory cytokine TNF. We propose that a humanized IgG4 anti-A antibody that takes
advantage of a uniqueAbinding profile, while also possessing reduced effector function,mayprovide a safer therapeutic alternative for
passive immunotherapy for AD. Data from a phase I clinical trial testing MABT is consistent with this hypothesis, showing no signs of
vasogenic edema, even in ApoE4 carriers.
Introduction
Alzheimer’s disease (AD) is the most common form of neurode-
generation and is exemplified by debilitating dementia. It is pro-
posed that -amyloid (A) peptides, the proteolytic products of
amyloid precursor protein, are toxic and causative in AD, con-
tributing to memory loss and neurodegeneration (Selkoe, 2002).
The A1–42 peptide is believed to be the most toxic species,
present in various conformational forms (Bitan et al., 2003;
Cleary et al., 2005; Shankar et al., 2007). Evidence suggests that
some degree of A1–42 oligomerization is necessary for neuro-
toxicity (Walsh et al., 2002; Kayed et al., 2003; Jan et al., 2011).
Furthermore, multiple soluble assembly forms of A1–42 are
thought to be both required and sufficient to disrupt neuronal
function and subsequent learning and memory (Cleary et al.,
2005; Townsend et al., 2006; Poling et al., 2008).
Structural alterations and oligomerization of A1–42 result
in a multifaceted dynamic equilibrium of small protofibrillar in-
termediates in which early oligomeric species act as seeds for
fibrillar plaques (Bitan et al., 2003) and thus are of great interest
as the primary targets of anti-A therapeutics. A passive anti-A
immunotherapy will likely be most beneficial by targeting multi-
ple A1–42 assemblies, including soluble oligomers (Walsh et
al., 2005), and other A peptide aggregates that contribute to
early events in the A1–42 oligomerization process (Frenkel et
al., 1998; Lambert et al., 1998; Lee et al., 2006; Spires-Jones et al.,
2009).
An active immunization approach using an A1–42 vaccine
was cut short due to safety concerns (Orgogozo et al., 2003), yet
some modest long-term functional benefits were reported in an-
tibody responders (Vellas et al., 2009). Active immunizationwith
A carries the risk of adverse immunological responses, leading
to inflammation such as meningoencephalitis (Orgogozo et al.,
2003), and also lacks the ability to regulate response level and
duration. To mitigate these risks, drug development has focused
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on passive immunizationwith antibodies targeting A. Although
safer, passive immunization may induce antibody–antigen com-
plexes that fully engage Fc receptors (FcRs) on microglia that
may provoke adverse proinflammatory reactions, possibly lead-
ing to blood–brain barrier (BBB) disruption observed as vaso-
genic edema and/or cerebral microhemorrhage (Salloway et al.,
2009).
Here, we describe a humanized anti-Amonoclonal antibody
[MABT5102A (MABT)] that targets different A assembly states
and contains a human IgG4 backbone with reduced effector
function (van der Zee et al., 1986; Tao et al., 1991). MABT effec-
tively reduces A1–42-induced neuronal death and notably pro-
motes microglial A engulfment, but has a significantly reduced
capacity to activate microglial FcRs when compared with an
IgG1 subclass.
To directly assess the potential improvement in safety profile,
MABTwas tested in a single dose, dose-escalation stage, followed
by a randomized placebo-controlled, double-blind, parallel mul-
tidose (MD) stage phase I clinical study. Patients were also ran-
domized in the MD stage by ApoE status, as previous studies
showed that ApoE4 carriers are at higher risk of developing vaso-
genic edema (Sperling et al., 2012). Consistent with our hypoth-
esis, MABT showed no signs of vasogenic edema at doses as high
as 10 mg/kg single dose, or 5 mg/kg MD over four doses. Phar-
macokinetic and pharmacodynamic analysis demonstrated a
dose-proportional increase in exposure to MABT and a robust
elevation in plasma total A levels, which correlated well with
serum MABT concentrations, thus confirming that MABT en-
gaged A in humans.
Materials andMethods
Cell culture preparation. Rat primary cortical cultures were prepared
from Sprague Dawley rats (Charles River Laboratories) of either sex at
postnatal day 1, as described by Meberg and Miller (2003). Cerebellum
andmeninges were removed, and cortices were cut into small pieces and
dissociated with enzymatic disruption at 37°C in dissociation buffer (pa-
pain, CaCl2, EDTA, and HEPES; all from Invitrogen). DNase (Invitro-
gen) was added for 10 min. Following dissociation, dispersed cortical
neurons were plated onto poly-L-lysine (0.01%; molecular weight,
150,000–300,000; Sigma-Aldrich)-coated 6-well, 24-well, or 96-well tis-
sue culture plates. For immunocytochemistry, cells were grown on
coated glass coverslips, into 24-well plates. Cells weremaintained inNeu-
robasal media (Invitrogen) without phenol red, with the addition of
L-glutamine (2 mM; Sigma-Aldrich), B27 supplement (Invitrogen), and
penicillin/streptomycin (Sigma-Aldrich) in a humidified incubator at
37°C and 5%CO2. Following 1 h and 30min in culture, the mediumwas
replaced with astrocyte-conditioned medium. After further 4 d in cul-
ture, cell proliferation was blocked by treatment with cytosine arabino-
side at 2.5 M (Invitrogen). Under these culture conditions, 20% of cells
were identified as neurons by NeuN/DAPI staining (data not shown).
Experiments using mixed cortical cells were generally performed after
culturing cells for 6 d in vitro, unless stated otherwise. Enrichedmicroglia
prepared from cortex and hippocampus were harvested as described for
cortical cultures above. Cortex and hippocampus were put in DMEM
containing high glucose and homogenized by pipetting with a 10 ml
pipette and then with a syringe. The homogenate was centrifuged for 3
min at 1000 g, and then resuspended in prewarmedDMEMcontaining
high glucose containing 10% FCS and penicillin/streptomycin (micro-
glia media). The cell suspension was next transferred to a T75 tissue-
culture flask and kept in a humidified incubator at 37°C and 5%CO2 for
1 week. The flask was shaken to separate microglia from adherent cells,
and collected and washed in DMEM. The resulting cells were resus-
pended in 1 ml of microglia medium, counted, and plated at 5  104
cells/well. To verify microglial enrichment, cells were stained with the
astroglial and microglial markers GFAP and Iba1, respectively. Greater
than 60% of cells stained positive for Iba1, with no cells staining for both
GFAP and Iba1. Pure microglia were prepared from postnatal day 3
CX3CR1-GFPmice (The Jackson Laboratory). Cortex and hippocampus
was dissected and triturated inDMEMcontaining high glucose using a 10
ml pipette, and then with an 18 gauge needle. The homogenate was
centrifuged for 3 min at 1000 g, and then resuspended in prewarmed
DMEM containing high glucose, 10% FBS, and penicillin/streptomycin
(microglia media). The cell suspension was next transferred to a T75
tissue culture flask and kept in a humidified incubator at 37°C and 5%
CO2 for 7–10 d. Microglia were isolated by shaking, collected, and
washed in DMEM. The resulting cells were resuspended in 1 ml of mi-
croglia medium, counted, and plated on tissue culture-treated glass
chamber slides at 5 104 cells/well for use in experiments.
Generation of anti-A antibodies and in vivo efficacy studies. The
disulfide-stabilized IgG4 anti-Amonoclonal antibody (mAb)MABT is
a humanized form of a mouse IgG2b mAb (mMABT) generated by im-
munizingmice with a vaccine prepared as previously described (Muhs et
al., 2007). For in vivo efficacy, both single-transgenic hAPP(V717I) and
double-transgenic hAPP(V717I)/PS1 female 8- to 9-month-oldmice were
administered 10 mg/kg purified mMABT once weekly, 2 or 14 times,
respectively. Brain A plaque load was evaluated by thioflavin-S staining
in the hAPP(V717I) mice, and memory performance by novel object rec-
ognition test using the hAPP(V717I)/PS1 mice.
A1–42 aggregation assay.A1–42 peptide (Bachem)was dissolved in
1,1,1,3,3,3-hexafluoro-2-propanol, sonicated, and shaken overnight at
room temperature. Aliquots were then dried under a flow of argon, vac-
uumdried, and stored at80°C asmonomeric A1–42 peptide film. For
inhibition of aggregation, antibodies were prediluted in PBS and then
added to nonsiliconized incubation tubes containing the following: 10
M thioflavin-T (ThT) (Sigma-Aldrich), 33 M A1–42 peptide film,
and 8.2% DMSO, with a final 10:1 molar ratio of A1–42 to antibody.
Incubation was done for 24 h at 37°C, and the spectrofluorescence (ex-
citation, 440 nm; emission, 485 nm) read in six replicates in a black
384-well plate (PerkinElmer) in a microplate reader (Tecan). For disag-
gregation of preaggregated A1–42, the A1–42 film was made up as a
110M solution in 27%DMSO and PBS. This solution was then allowed
to aggregate at 37°C for 24 h, after which the following were added:
prediluted antibody with a final 10:1 molar ratio of A1–42 to antibody
and 10 M ThT. This solution was then incubated for additional 24 h at
37°C, after which spectrofluorescence was measured as described above.
Inhibition of aggregation and disaggregation is expressed as mean per-
centage (SEM) inhibition or disaggregation, respectively.
FcR binding. The binding of test antibodies to a panel of human
FcRswasmeasured using ELISA.Human FcRs (Genentech) are fusion
proteins containing the extracellular domain of the receptor -chain
with a Gly/6xHis/glutathione S-transferase (GST) polypeptide tag at the
C terminus. A mAb with a human IgG1 framework was used as the
positive control (IgG1 control) in this experiment. Plates were coated
with a mouse monoclonal anti-GST antibody (Genentech) in a 0.05 M
sodium carbonate buffer, pH 9.6, overnight at 4°C. After blocking with
an assay buffer containing PBS, 0.5% BSA, and 0.05% Tween 20, the
plates were incubated with FcRs at room temperature for 1 h. Human
FcRs were immobilized to the plate via interaction with the anti-GST
coating. Serial dilutions of anti-A MABT, MABT-IgG1, MABT-IgG1-
D265A, or IgG1 control mAbs were prepared in the assay buffer contain-
ing 10% Blocker Casein in PBS (Pierce). Diluted samples were applied as
monomeric forms for the high-affinity receptor (FcRIa), or multimeric
forms for the low-affinity receptors (FcRIIa, FcRIIb, and FcRIIIa).
The multimeric forms of test antibodies were generated by cross-linking
F(ab)2 fragment of goat anti-human -chain (MP Biomedicals), with
test mAb at an approximatemolar ratio of 3:1. The plates were incubated
with FcRs at room temperature for 2 h. Plates were washed three times
with wash buffer containing PBS and 0.05%Tween 20 after each incuba-
tion step. The antibodies bound to the FcRs were detected with horse-
radish peroxidase-conjugated F(ab)2 fragment of goat anti-human
F(ab)2 (Jackson ImmunoResearch Laboratories). Tetramethylbenzi-
dine (Kirkegaard & Perry Laboratories) served as a substrate. Plates were
incubated at room temperature for 15–20 min to allow color develop-
ment. The reaction was terminated with 1 M H3PO4, and absorbance at
450 nm with reference at 650 nm was measured on a plate reader (Mo-
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lecular Devices). Binding curves were generated by plotting the mean
absorbance values fromduplicates of sample dilutions against the respec-
tive sample absorbance.
Preparation of toxic A1–42 oligomers.A1–42 peptide (Bachem) film
was prepared as described above. A 165 g aliquot of peptide film was
resuspended in 7 l of DMSO, 85 l of PBS, and 9 l of 2% SDS and
incubated for 6 h at 37°C. Then, 300 l of water was added, and after an
overnight incubation at 37°C, A1–42 oligomers were precipitated with
900 l of 33% methanol 4% acetic acid solution for 1 h at 4°C, centri-
fuged at 16,200 g for 10 min. Supernatant was removed and A1–42
oligomers were dried before being resuspended in Na2HPO4/NaCl solu-
tion for a final concentration of 1 g/l.
A1–42 cellular toxicity assays. The cytotoxicity of A1–42 oligomers
was tested on mixed cortical cultures at day in vitro 5 (DIV 5). All anti-
bodies, at a final concentration of 100 g/ml, were coincubated with
A1–42 oligomers for 30min in serum-free cell culture medium at 37°C
before treatment of cells. For some experiments, mixed cortical cultures
were pretreated for 1 h with 1 M trans-4-[4-(4-fluorophenyl)-5-(2-
methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol (SB239063), a
p38MAPK inhibitor, before treatment with A1–42 oligomers. Cell via-
bility was performed by standardized 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction assays (Promega),
following the manufacturer’s instructions. Briefly, for the last 3 h of
treatment, cells grown in 96-well plates (Costar) were incubated with the
MTT dye solution and the generation of a blue formazan product was
measured by reading absorbance at 570 and 690 nm using a microplate
reader (Tecan). Results are presented as a percentage increase in survival
over A1–42 oligomer-treated cells. The ability of the MABT mAb to
protect neurons from A1–42 oligomer-induced degeneration was also
assessed in an in vitro assay using immunofluorescence. Embryonic day
17.5 mouse cortical neurons were isolated, dissociated, and cultured in
vitro in Neurobasal media with B27 supplement. A1–42 was prepared
as described above for A1–42 monomeric peptide film, after which 10
l of DMSO was added to dissolve the peptide. Then, 78.6 l of Ham’s
F12 media was added and the A1–42 peptide solution at 25 M was
incubated at 4°C for 48 h before cell treatment. Cells were grown for 9 d
in total, andwere fed onday 3 andon the day of treatment. For treatment,
A1–42 at 2 M with or without MABT at 50 g/ml was added at day 5
or day 6, with DMSO-F12 alone at the same volume used for the vehicle
control. Onday 9, following 3 or 4 d of treatment, neuronswere fixed and
stained with anti-TuJ1 antibody at 1:1000 dilution. FITC- or Alexa Fluor
488-labeled secondary antibodies were used to visualize TuJ1microtu-
bules using fluorescence microscopy.
Immunohistochemistry. Paraffin-mounted temporal lobe brain sec-
tions (20 m) from an AD patient and from an age-matched non-AD
control (Tissue Solutions) were used for immunohistochemistry stain-
ing. Deparaffinized sections were subjected to antigen retrieval using
formic acid and then labeled with 50 g/ml MABT as the primary anti-
body. A goat anti-human biotinylated IgG was used as a secondary anti-
body. Staining was done with diaminobenzidine (Dako) and mounting
using Eukitt mounting medium. Images were acquired on a LSM 700
inverted microscope from Zeiss (Carl Zeiss).
Immunocytochemistry and confocal imaging. Cells were grown on glass
coverslips. Following treatment, cells were quickly washed with PBS and
then fixedwith 4%paraformaldehyde for 20min. After thoroughwashes,
cells were immersed in 100%methanol for 10 min at20°C. They were
then washed again and incubated in a blocking solution, PBS containing
10% normal goat serum for 1 h at room temperature. After an overnight
incubation with the primary antibody, cells were washed and incubated
for 2 h with the secondary antibody, and then washed and mounted on
glass slides using ProLong Gold antifade reagent (Invitrogen). Epifluo-
rescence and confocal images were acquired on a LSM 700 inverted mi-
croscope from Zeiss AG, using a 63 lens. Fluorescence intensity was
measured in cell bodies delineated by saturated epifluorescence pictures.
Z-stacks were rendered into a three-dimensional image using ImageJ
1.42 (National Institutes of Health; freeware) from which an apical-to-
distal slice containing the labeled proteins was obtained. Cells treated
with HyLite Fluor 488-tagged A1–42 were treated in the same way
except no primary or secondary antibodies were used to label for
A1–42. Puremicroglial cultures fromCX3CR1-GFP P3 pups were treated
with1g/ml lipopolysaccharide (Sigma-Aldrich), 10MA1–42oligomers
alone or in combination with 100 g/ml anti-A MABT, MABT-IgG1,
MABT-IgG1-D265A, control IgG1, or antibodies alone for 30 min. Cells
were fixed with 4% paraformaldehyde, washed, permeated with coldmeth-
anol, blocked with 10% goat serum in PBS, and stained with rabbit anti-
phospho-p38MAPK antibody (Cell Signaling Technology).
In vivo imaging of amyloid plaques. Cranial windows were implanted
above the somatosensory cortex of 10-month-old transgenic hAPP(V717I)/
PS1 femalemice, as previously described (Trachtenberg et al., 2002;Holt-
maat et al., 2009), 2 weeks before the initial imaging session. Twenty-four
hours before each imaging session, animals were peripherally injected
with 10 mg/kg methoxy-X04 intraperitoneally to visualize individual
amyloid plaques (Klunk et al., 2002) and immediately before imaging
injected intravenously with AngioSense680 (VisEn Medical) to visualize
blood vessels. For each imaging session, animals were anesthetized with
an isoflurane–oxygen mixture and mounted to the microscope using a
head post. Images were collected via a two-photon laser-scanningmicro-
scope (Ultima In Vivo Multiphoton Microscopy System; Prairie Tech-
nologies) using a Ti:sapphire laser (MaiTai DeepSee Spectra Physics;
Newport) tuned to 820 nmdelivering30mWto the back-focal plane of
a 40, NA 0.8 objective lens (Olympus Imaging). The pattern of the
vasculature was used to reproducibly position the mouse relative to the
objective from day-to-day enabling individual amyloid plaques to be
imaged over many weeks. The volumes of individual plaques were esti-
mated by summing the number of pixels above background within a
region of interest drawn around a given plaque. Background is defined as
the mean pixel intensity plus 2 SDs within a region of interest drawn
adjacent to an amyloid plaque. Following the fourth and eighth imaging
session, animals were dosed intraperitoneally with 60 mg/kg MABT.
Phospho-p38MAPK ELISA. Rat cortical cultures were seeded onto
poly-L-lysine-coated six-well cell culture plates (Costar) and used at DIV
5. Unless otherwise indicated, cells were treated with 2 M A1–42 oli-
gomers with or without mAb at 100 g/ml for 30 min. In some assays,
cells were pretreated for 1 h with the p38MAPK inhibitor SB239063.
Anisomycin was used as a positive control. Treatments were stopped by
placing cells on ice and aspirating the medium. Cells were washed with
ice-cold PBS, harvested using a cell scraper, and lysed in buffer consisting
of 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 mM sodium
orthovanadate, 1% Triton X-100, and containing protease and phos-
phatase inhibitor cocktails. Protein concentration was determined by
the BCA assay (Pierce). For semiquantitative measure of p38MAPK
activation, a rat phospho-p38MAPK colorimetric ELISA kit was used
(Cell Signaling Technology), following manufacturer’s instructions.
Plates were read on a spectrophotometric microplate reader (Tecan)
at a 370 nm.
TNF release. Rat cortical cultures enriched for microglia (60%
Iba1 of total DAPI cells) were treated with 10 M A1–42 oligomers
with or without 100 g/ml antibodies for 6 or 24 h. Lipopolysaccharide
(Sigma-Aldrich) at 1 g/ml was used as a positive control stimulus. Cell
supernatants were removed at the indicated time points, passed through
a 0.2 m filter, and tested for TNF with a Quantikine rat TNF/
TNFSF1A (R&D Systems), following the manufacturer’s instructions.
Statistical analysis. All statistical analyses were done using GraphPad
Prism, version 5 (GraphPad Software). Data are presented as means 
SD or SEM, as indicated. Data were analyzed by Student’s t test, one-way
ANOVA followed by Tukey’s post hocmultiple comparisons, or Wilcox-
on’s rank sum nonparametric test when appropriate. A value of p 0.05
was taken to indicate a statistically significant difference.
Results
Generation of a humanized IgG4 antibody, MABT, that binds
multiple A conformations
Murine anti-A monoclonal antibodies were generated by im-
munizing mice with an A peptide antigen using a liposomal
vaccine formulation as previously described (Muhs et al., 2007;
Hickman et al., 2011). Several criteria were used to select candi-
date antibodies, including the ability to bind multiple A species
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and to inhibit A1–42 assembly into
small cytotoxic peptide aggregates. A
monoclonal murine mAb with an IgG2b
backbone (mMABT) was selected for in
vivo efficacy studies using both single-
transgenic hAPP(V717I) and double-
transgenic hAPP(V717I)/PS1 female mice.
When compared with vehicle control,
treatment with mMABT reduced plaque
load in mMABT-treated mice by 31%,
and improved memory performance with
a 32% increase in recognition index as ob-
served in a novel object recognition test
(Fig. 1A). The mMABT was further affin-
ity matured and humanized onto an IgG4
backbone (referred to as MABT). To test
the binding of MABT to A in vitro, we
made a series of different A1–42 prepa-
rations. The binding of MABT was mea-
sured by ELISA, and similar to the
mMABT (Fig. 1B), was shown to be
highly comparable among the different
A peptides (Fig. 1C) or A1–42 assem-
bly states (Fig. 1D).
MABT was subsequently tested for
binding to A plaques in the brains of
transgenic mice expressing the human
amyloid precursor protein (hAPP(V717I))
and to amyloid plaques in human AD
brain sections. Amyloid plaques in both
hAPP(V717I) transgenicmice (Fig. 1E, top)
and in AD brain (Fig. 1E, bottom) were
immunodecorated with the MABT mAb.
Together, these data provide evidence of
MABT binding to both soluble A oli-
gomers and A aggregates present in AD
brains.
Inhibition of A assembly and
disaggregation of preformed
protofibrillar A peptides by MABT
The binding epitope ofMABTwasmapped
to amino acids 12–23 of A1–42, and
therefore overlaps with the main hydro-
phobic cationic segment of A1–42
responsible for the self-association, subse-
quent oligomerization, and the core of
A1–42 -sheet assembly (Pike et al.,
1993; Esler et al., 1996; Haass and Selkoe,
2007). We therefore hypothesized that
MABT would inhibit A1–42 assembly
and possibly dissociate preaggregated
A1–42. This prompted us to evaluate the
effects of MABT on in vitro A1–42 ag-
gregation using ThT, a dye that does not impede with amyloid
assembly but fluoresces upon binding to amyloid aggregates rich
in -sheets (LeVine, 1993). When we comparedMABT to a con-
trol anti-A mAb directed against the N terminus of A1–42,
and thus not overlapping with the core amino acids that form the
self-assembly domain, MABT demonstrated 83% greater inhibi-
tory effect on A1–42 aggregation in a ThT assay (Fig. 1F, left
panel). Similarly, an 80% greater dissociation of preaggregated
A1–42 peptide was observed, when compared with the control
N terminus anti-A mAb (Fig. 1F, right panel). These in vitro
assays are based on the ability of ThT to bind to extended-sheets
of the A1–42 peptide (LeVine, 1993). Therefore, to verify that
this was not an artifact due to potential mAb-mediated displace-
ment of ThT binding to -sheet rich A1–42, we performed an
assay that does not rely on ThT fluorescence, but rather on the
capacity of labeled A1–42 to aggregate or self-assemble onto
immobilized unlabeled A1–42. We obtained comparable re-
sults in this assay, namely thatMABTprevented the self-assembly
Figure 1. The anti-AMABTmAb binds with high affinity to different A peptides and has antiaggregation properties. A, An
in vivo efficacy study administering mMABT to hAPP (V717I) mice showed a reduction in A plaque load (left panel) and improved
memoryperformance (right panel). Results showmeans (95%CI).B,C, AnA ELISAwasused to compare thebinding tohuman
and murine A1–42 and human A1–40, for mMABT (B) and MABT (C). D, MABT was also tested for binding to different
A1–42assembly states, showing equal binding for oligomers,monomers, and fibers.E,MABTbindsAplaques present in brain
sections from transgenic hAPP (V717I) mice (top panels) and human AD temporal neocortical sections (bottom panels). F, In vitro
functionality was shown by the ability of MABT to impede A1–42 aggregation (left panel), and to disassemble preformed
A1–42 aggregates (right panel) in a ThT-based assay, with an A1–42 to MABTmolar ratio of 10:1. An anti-A IgGmAbwith
a N-terminal epitope was used as control. Results show the mean (SD) of three independent experiments. *p 0.05; **p
0.01. G, MABT was also tested in an A1–42 self-assembly assay that does not rely on ThT fluorescence upon binding to multi-
meric A assemblies, as described in Materials and Methods. The means (SEM) of two assays are shown.
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of A1–42 in a dose-dependent manner (Fig. 1G). These data
suggest that an antibody directed against the mid-domain of A,
yet maintaining binding to aggregated A, may provide the most
robust inhibitory effect on A1–42 fibril elongation and/or ag-
gregation relative to antibodies targeting other domains of A.
MABT neutralizes the neurotoxic effects of A oligomers
in vitro
Wenext investigated the effects ofMABT in a primary cell culture
model using cytotoxic A1–42 oligomers. Primary cortical cul-
tures from P1 rats were grown and treated with free A1–42
oligomers or oligomers bound to MABT. Treatment of cortical
cultures with 2.5 or 5MA1–42 oligomers over 24 h resulted in
a reduction in metabolic activity as measured by mitochondrial
oxidation ofMTT (Fig. 2A), an indicator of cell viability. A com-
plete rescue from toxicity was observed for A1–42 oligomer
concentration up to 5 M in the presence of MABT (MABT to
A1–42 molar ratio of 1:7.5) compared with control IgG. To
confirm these results, ATP release wasmeasured using a lumines-
cence assay, showing a similar neuropro-
tective effect of MABT (Fig. 2B). To
further assess the effect ofMABTonA1–
42-mediated neurodegeneration, mouse
embryonic cortical neurons were cultured
for 6 d, and treated with A1–42 with or
without MABT for 4 d. Control cultures
showed healthy morphology (Fig. 2C, left
panel). Treatment with A1–42 for 4 d
resulted in robust neurite degeneration
(Fig. 2C, center panel). Cells treated with
the combination of A1–42 and MABT
appeared similar to control cells (Fig. 2C,
right panel). For these assays, a mixture of
cytotoxic A1–42 oligomer assemblies
was used, ranging in size from dimers
and trimers to higher-molecular-weight
multimers (Fig. 2D). These results show
that MABT was able to protect primary
neurons from A1–42 oligomer-induced
degeneration.
A1–42 oligomer interaction with
neurons is inhibited by MABT
A peptides, especially aggregation inter-
mediates (Bateman et al., 2007), are
known to associate with various lipids and
proteins present in cell membranes. We
hypothesized that MABT may exert its
neuroprotective effects by reducing bind-
ing of A1–42 oligomers to neurons. To
test this idea, an immunofluorescent
staining for membrane-bound A was
performed. A1–42 oligomers were ap-
plied tomixed cortical cultures for 30min
or 18 h, after which cultures were stained
for A and the neuron-specific class III
-tubulin, TuJ1. We observed that treat-
ment of cortical neurons with A1–42
oligomers resulted in A binding to neu-
rons, particularly localized to neuritic
processes (Fig. 3A, middle panels and in-
sets). Cotreatment with MABT blocked
the interaction of A1–42 oligomers with
neurons. This effect was readily apparent as early as 30 min (Fig.
3A,B) and remained for at least 18 h of treatment (Fig. 3B).
Although we used an N-terminal anti-A mAb (clone 6E10) to
stain for A1–42 oligomers in our assay (Fig. 3A), thus reducing
the potential for interference between MABT and the detection
mAb used for staining, we confirmed these results using HiLyte
Fluor-488 fluorescently labeled A1–42. Treating cortical cul-
tures with this directly labeledA1–42 peptide further supported
the conclusion that MABT reduced binding of A1–42 to neu-
ronal processes in primary cortical cultures (Fig. 3C,D).
Observations from immunofluorescent studies also indicated
that, in the presence of MABT, there was a shift in A1–42 oli-
gomer association away from neuronal processes toward cellular
profiles that resembledmicroglia (Fig. 3E). This may be expected
for an antigen–antibody complex binding to microglia through
an FcR-mediated mechanism (Clark, 1997), but was unex-
pected for the effector-reduced MABT, which required further
investigation.
Figure 2. The MABT inhibits cytotoxicity of A1– 42 oligomers on primary mixed cortical cultures. A, Mixed cortical cells
from P1 rats were treated with 2.5 or 5M A1– 42 oligomers with or without 100g/ml of MABT or an IgG control mAb.
An MTT assay was used to determine cell viability as described in Materials and Methods. The means (SEM) of five
independent experiments are shown. *p 0.05; **p 0.01. B, In a comparable assay, but measuring ATP production as
amarker of metabolic activity, cells were treated with 10M A1– 42 oligomers with or without 200g/ml MABT. Results
show the means (SEM) of two independent assays. C, Neurotoxicity following extended A1– 42 oligomer treatment
was tested by morphological analyses. Cells as above were treated for 4 d with 10M A1– 42 oligomers, with or without
50 g/ml of MABT, and then stained for TuJ1 (green) and DAPI (blue). D, Silver-stained SDS-PAGE showing the highly
cytotoxic A oligomer preparations consisting of a mixture of A1– 42 oligomer assemblies, ranging in size from dimers
and trimers to higher-molecular-weight multimers.
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A role for effector function in
microglial uptake of A oligomers
We next explored the relationship be-
tween MABT/A1–42 complex forma-
tion andmicroglial uptake of A1–42. To
verify that A1–42 oligomers bound to
MABT are indeed taken up by microglia,
confocal imaging on treatedmixedneuro-
nal cultures was performed. When com-
pared with cells treated with A1–42
oligomers alone, we found that MABT
mediated rapid uptake of A1–42 oli-
gomers into cellular profiles likely to be
microglia (Fig. 4A). This was readily ap-
parent as early as 30 min following treat-
ment. Microglia play a crucial role in
uptake and degradation of A, a function
that is postulated to be compromised in
APPtransgenicmice (Hickmanet al., 2008).
Relative to anti-A immunotherapy, it has
been proposed that one possible mecha-
nism whereby A plaques are cleared is
through the FcR binding properties of
anti-A bound to A (Koenigsknecht-
Talboo et al., 2008).However, uptake of an-
ti-A/A complexes bymicroglia andFcR
activationmay trigger these cells to become
activated.
In addition to overcoming the direct cy-
totoxicityofA1–42oligomersonneurons,
a therapeutic anti-A antibody ideally
would have a reduced proinflammatory re-
sponse. We therefore compared MABT to
antibodies carrying the same antigen bind-
ing sequences, but harboring different IgG
backbones with variable FcR binding af-
finities, and therefore different microglia
activating potential. These included a
wild-type human IgG1 with full FcR
binding capacity (MABT-IgG1), and a
human IgG1 backbone carrying a D265A
mutation (MABT-IgG1-D265A) that dra-
matically reduces FcR binding (Shields
et al., 2001). All of the backbone variants tested bound with sim-
ilar affinity to A1–42, as verified using surface plasmon reso-
nance (data not shown). The ability of these different mAb
backbones to internalize A1–42 oligomers into microglia was
then compared using confocal imaging on A1–42 oligomer-
treated primary cortical microglia. We found that A1–42 oli-
gomer internalization correlated well with FcR binding, with
MABT-IgG1  MABT  MABT-IgG1-D265A (Fig. 4B,C). To
verify that microglia are indeed the cells taking up A1–42 com-
plexed to mAbs, we repeated the study using HiLyte Fluor 488-
tagged A1–42 and costained for the microglial marker Iba1.
Upon binding to either MABT or MABT-IgG1, tagged A1–42
became enriched in Iba1microglia (Fig. 4D). We also observed
that, in cell cultures treated with A1–42 in combination with
MABT-IgG1, microglia had more condensed nuclei and brighter
Iba1 staining, features suggesting greater antigen/antibody-
mediated microglial activation.
To verify the differences in FcR binding between MABT
backbone variants, we measured the binding of the different
cross-linked IgG mAb to FcRIIIa-V158 and, as expected,
found a hierarchy of binding such that MABT-IgG1 
MABT  MABT-IgG1-D265A (Fig. 4E). Comparable results
were obtained with other members of the FcR family (data
not shown).
We next compared the differentMABT variants for their abil-
ity to reverse A1–42 oligomer-mediated toxicity in mixed pri-
mary cortical cultures. Functional FcR binding activity, present
for both theMABT andMABT-IgG1mAbs, was required for full
reversal of A1–42 oligomer-mediated toxicity (Fig. 4F). The
MABT-IgG1-D265A mAb, which lacks FcR binding function-
ality, showed only a nonsignificant trend toward reversal of
A1–42 oligomer-mediated cellular toxicity. Perhaps surpris-
ingly, the MABT-IgG1 wild-type mAb, which bears greater FcR
binding affinity compared with the IgG4MABT, trended toward
a smaller protective effect when compared with MABT. We hy-
pothesized that, while binding to microglial FcRs is needed for
full rescue, the enhanced binding of theMABT-IgG1 backbone to
FcRs compared with that of a MABT may result in undesired
microglia activation, which may translate into reduced overall
protection against A1–42 oligomer-mediated neurotoxicity.
Figure 3. A1–42 oligomer binding to neurites is reduced by the anti-A IgG4mAb. A, Mixed cortical cells from P1 rats were
treated with 2M A1–42 oligomers, with or without 100g/ml of the MABT or an IgG control for 30min. The panels from left
to right show the following: treatmentwith buffer control, A1–42oligomers, andA1–42oligomerswithMABT. Green is TuJ1,
red is anti-A (clone 6E10), and blue is DAPI. The bottom row shows all three markers, whereas the top row shows only A and
DAPI. The two insets illustrate the binding of A1–42 oligomers to neurites (left) and the inhibition of this binding by the MABT
mAb (right). B, Quantitative measures of fluorescence are shown for 30 min and 18 h treatments. Mean results (SEM) of two
experiments are shown. C, A1–42 tagged with HyLite Fluor-488 verifies that MABT inhibits binding of A1–42 to neurites.
Cortical cultures from P1 rats were treated as described for A, except that A1–42 tagged with HyLite Fluor 488 was used. Green
is A1–42 and blue is DAPI, with one representative experiment shown. D, Green fluorescence was quantified, with the mean
(SD) of the two independent experiments shown. E, Upon treatment with MABT, A1–42 oligomers appeared to be taken up
by cells resembling microglia. Green is A1–42 and blue is DAPI.
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Therefore, in addition to having the ideal A binding properties,
optimizing the level of microglial activation may be crucial in
developing an anti-A therapeutic antibody with the desirable
safety and efficacy properties.
Having observed that MABT can efficiently promote A en-
gulfment by microglia in vitro, we assessed whether systemic ad-
ministration of MABT in hAPP(V717I) transgenic mice could
induce amyloid plaque removal in vivo. As the antibodies we
Figure 4. A1–42 oligomers are taken up via an FcR-mediatedmechanism intomicroglia uponMABT treatment. A, Confocal imagingwas used to show that A1–42 oligomers complexed to
MABT are taken up into microglia. A1–42 oligomers are shown in red, and blue is DAPI. An apical-to-distal slice was obtained from a three-dimensional image rendered from Z-stacks. Confocal
imaging was done on mixed cortical cells labeled for A (red) and DAPI (blue) as described in Materials and Methods. B, C, Microglia were identified and scanned for the maximum fluorescence
intensity through a series of confocal stacks representing intracellular locations (B), and the total area of fluorescent signal above aminimum threshold was quantified (C). Eachmark on the graph
represents the total area of A stainingwithin a single cell. Aminimum of 20 cells was analyzed for each treatment condition. Data were compared using one-way ANOVA followed by Tukey’s post
hoc multiple comparison. Means (SEM) are shown. D, Microglia (Iba1) was verified as the cell type taking up A1–42 complexed to MABT. Red is Iba1, green is HyLite Fluor 488-labeled
A1–42, and blue is DAPI. E, Differential binding to FcRIIIa-V158 was verified in a binding assay. F, An anti-AmAb requires effector function via FcR binding for full protective effect against
A1–42 oligomer toxicity.Mixed cortical cells fromP1 ratswere treatedwith A1–42 oligomers,with orwithoutMABT,MABT-IgG1-D265A,MABT-IgG1, or an IgG1 controlmAb. The graph shows
the mean (SEM) percentage increase in cell survival compared with A1–42 oligomer treated cells, from five independent experiments. Statistical analysis was done using one-way ANOVA
followed by Tukey’s post hocmultiple comparison.
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generated used human backbones, we were unable to conduct
chronic dosing studies as is commonly done for murine antibod-
ies, both because human antibodies can robustly induce an anti-
therapeutic antibody response and because there is not a murine
version of human IgG4 that replicates the Fc receptor binding
profile (Fig. 4E). Thus, using in vivo live-imaging preparations in
a short course of dosing, we confirmed the ability of MABT to
promote glial engulfment of A by analyzing individual plaques
in 10-month-old hAPP(V717I)/PS1 transgenic mice over several
weeks (Fig. 5A). On average, individual plaques increased in vol-
ume over the initial 3 week imaging period (Fig. 5B, average
week-to-week normalized change in volume; 0.156, 0.060, and
0.081). Following a single peripheral MABT administration (60
mg/kg, i.p.), plaque volume decreased over the 3 week period
after dosing (average week-to-week normalized change in vol-
ume;0.036,0.034, and0.034). A second dose ofMABTwas
administered to a single animal and seven plaques were followed
by imaging, three of which were completely removed by week 9.
These observations are consistent with our in vitro data suggest-
ing thatMABT can induceA removal, presumably viamicroglia
uptake.
Reducedmicroglia response with MABT
To identify downstreammediators of A1–42 oligomer-induced
toxicity, we examined a number of candidate signaling pathways.
We focused our efforts on examining p38MAPK, which has been
shown to contribute to neurotoxicity and microglial activation
(Li et al., 2004; Wang et al., 2004). We first examined p38MAPK
activation in primary mixed cortical cultures treated with
A1–42 oligomers alone, or in combination with the anti-A
MABT, MABT-IgG1, MABT-IgG1-D265A, or a control IgG1
that does not bind to A. When cells were treated with A1–42
oligomers, p38MAPK was activated within 15 min (data not
shown) and reached amaximumat 30min. After combiningwith
the different mAbs, only MABT-IgG1, carrying the IgG1 wild-
type backbone and thus having the greatest binding affinity to
FcR, significantly increased the A1–42 oligomer-induced
p38MAPK activity above A1–42 baseline levels, as shown by a
phospho-p38MAPK-specific ELISA (Fig. 6A). Since the various
anti-A antibodies bind with similar affinity to A1–42, the
MABT-IgG1 mAb should neutralize toxic A1–42 oligomers to
the same degree as MABT. However, the greater FcR binding
affinity of the IgG1 backbone may result in microglia activation
that can be detrimental to cells that are highly susceptible to the
actions of A1–42 oligomers, such as neurons. MABT com-
plexed to A1–42 oligomers did not reduce the A1–42
oligomer-induced p38MAPK activity, but rather showed a trend
toward higher activity, possibly reflecting the partial FcR acti-
vation by this antibody.
As these initial assaysmeasured the total p38MAPK activity in
mixed cortical cultures, including both neuronal and glial cells,
we wanted to know whether the p38MAPK activity detected
when cells were treatedwith the combination of A1–42 oligom-
ers and MABT was specific to microglia. Cells were treated as
previously, but this time phospho-p38MAPK activity was exam-
ined by immunofluorescence staining along with the microglia
marker Iba1. Upon treatment with A1–42 oligomers com-
plexed to MABT or MABT-IgG1 mAbs, 93% of cells staining
positive for phospho-p38MAPK were Iba1 (Fig. 6B). To con-
firm the activation of p38MAPK inmicroglia, we treated purified
microglia in the same way. Under these conditions, A1–42/IgG
complex-mediated p38MAPK activation inmicroglia was readily
identified (Fig. 6C).
To address the contribution of p38MAPK activation to
A1–42 oligomer-mediated neurotoxicity, we next treated cells
with a second-generation p38MAPK-specific inhibitor, and then
with A1–42 oligomers alone or in combination with either the
MABT or the low-FcR binding MABT-IgG1-D265A mAb. Un-
expectedly, the MABT-mediated increase in MTT signal was re-
duced to that of MABT-IgG1-D265A in presence of the
p38MAPK inhibitor, indicating a reduction in MABT-mediated
rescue function upon p38MAPK inhibition (Fig. 6D). As pre-
dicted, p38MAPK inhibition had no effect on cells treated with
A1–42 oligomers complexed with the MABT-IgG1-D265A
mAb. This indicates that, although the MABT mAb does not
significantly induce p38MAPK levels over those seen with
A1–42 oligomers alone, p38MAPKactivation does play a role in
MABT-mediated neuroprotection. The cellular target of this ac-
tivity in the mixed culture system is not known.
To link the increased microglia activity more directly to a
downstream proinflammatory readout, we measured TNF re-
lease by primary cell cultures enriched for microglia (61%
Iba1; data not shown). The release of proinflammatory TNF
by enriched microglia when treated with A1–42 oligomers was
reduced in the presence of all anti-A mAbs tested (Fig. 6E).
However, the greatest effect was observed in the presence of
MABT. Thus, MABT has amore desirable profile compared with
MABT-IgG1, combining both the neuroprotective effects with
the ability to promote A engulfment by microglia with limited
microglial activation. Similar results were observed when evalu-
ating other canonical cytokines; however, these cytokines were
not consistently upregulated by the addition of our A oligom-
Figure 5. Systemic dosing of MABT modulates individual amyloid plaques in vivo. A, Amyloid plaques in hAPP (V717I)/PS1 animals were labeled with methoxy-X04 injected intraperitoneally,
visualizedby in vivo two-photonmicroscopy, and trackedovermultipleweeks.B, The relative change inplaque volumeover timeplottedas fold increase fromthe initial imaging session.Onaverage,
the individual plaque size decreased in volume after systemic dosing with MABT (14 plaques, 2 animals).
9684 • J. Neurosci., July 11, 2012 • 32(28):9677–9689 Adolfsson et al. • Effector-Reduced Anti-A Antibodies
Figure 6. MABT reduces microglial activation as measured by p38MAPK activity and TNF secretion. A, When complexed to A1–42 oligomers, the IgG1 wild-type backbone significantly
increases p38MAPKactivation over that shown for A1–42oligomer-treatedmicroglia.Mixed cortical cells fromP1 ratswere treatedwith 10MA1–42oligomers for 30minwith orwithout 100
g/ml MABT, MABT-IgG1-D265A, or MABT-IgG1wild type. An IgG1mAb not binding to Awas used as control. The activity of p38MAPKwasmeasured by a phosphospecific ELISA as described in
Materials and Methods. The mean (SEM) of four independent experiments is shown. Statistical analysis was done using one-way ANOVA followed by Tukey’s post hocmultiple comparison. B,
Activation of p38MAPKwith A1–42 oligomers complexedwithmAb is specific tomicroglia. Cells were treated as described above and then stained for phospho-p38MAPK (green), Iba1 (red), and
DAPI (blue). The panels from left to right show the following: treatmentwith buffer control, A1–42 oligomers, and A1–42 oligomerswithMABT. C, Puremicroglia from CX3CR1-GFPmicewere
used to verifymicroglia-specific p38MAPK activity. The top panels showphospho-p38MAPK immunofluorescence (red), whereas the bottompanels are amerge of phospho-p38 and GFP (green) on
a phase contrast image.D, p38MAPK activity is required for the full protective effect of MABT against A1–42 oligomer toxicity.Mixed cortical cells fromP1 ratswere treated (Figure legend continues.)
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ers; thus, our efforts were focused on evaluating p38MAPK acti-
vation and TNF secretion as consistent measures of microglial
activation.
Reduced risk of vasogenic edema withMABT observed in a
phase I clinical study
A phase I, randomized, placebo-controlled, double-blind, multi-
center clinical study was conducted with the primary objective to
determine the safety and tolerability of intravenous MABT in
patients with mild-to-moderate AD. Secondary objectives of this
study were to characterize pharmacokinetics and A pharmaco-
dynamics after single and multiple doses of MABT in AD pa-
tients. The study consisted of a single-dose (SD), dose escalation
stage, followed by a randomized placebo-controlled, double-
blind, parallel multidose (MD) stage (Fig. 7A). The main patient
selection criteria included diagnosis of AD (National Institute of
Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association criteria),
mini-mental state examination score of 15–26 (inclusive) at
screening, and a 50–86 years of age range. The actual patient
population included in the study are outlined in Figure 7B.
No patients receiving MABT developed vasogenic edema, in
either the single or multidose study. Importantly, patients were
genotyped and randomized in the multidose study to ensure that
at least 40% of enrolled patients were ApoE4 carriers (48% were
carriers), as these patients were previously shown to be at higher
risk of developing vasogenic edema (Salloway et al., 2009). The
serum concentration–time profiles for MABT following both a
single dose (0.3–10 mg/kg) and four weekly doses (0.5–5 mg/kg)
increased in proportion to dose and were characterized by slow
clearance (3 ml  d1  kg1) and a long half-life (18–23 d)
(Fig. 7C). A dose-dependent elevation in plasma total A levels
was observed following single or weekly intravenous administra-
tion, which correlated well with serum MABT concentrations
(Fig. 7D), thus suggesting substantial target engagement in vivo.
These data suggest that an anti-A antibody targeting a wide
array of A assembly states, including aggregated A, combined
with a human IgG4 backbonewith reduced effector function, can
be safely dosed in humans at relatively high levels, thus improving
CNS exposure. Additional clinical trials are underway to assess
the efficacy of MABT (crenezumab).
Discussion
Recent clinical results using both active and passive immuniza-
tion to target A in AD patients have identified a number of
challenges (Orgogozo et al., 2003; Lee et al., 2005; Salloway et al.,
2009); thus, great emphasis has been placed on developing alter-
native strategies toward a safer and more effective immunother-
apy for AD. Amajor theme of the safety findings from these trials,
particularly with passive immunotherapy, is disruption of the
BBB as observed bymagnetic resonance imaging showing signs of
vasogenic edema and/or microhemorrhages (Salloway et al.,
2009). Mechanisms underlying these dose-limiting observations
have been proposed (for review, seeWeller et al., 2009). A prom-
inent immunotherapy-specific hypothesis is that the immune
functions of the particular anti-A antibody and/or its binding
properties are central to the risk associated with these BBB integ-
rity findings (Wilcock et al., 2004, 2006). It has also been hypoth-
esized that these safety findings are inseparable from the
mechanisms driving efficacy of immunotherapy (Weller et al.,
2009); however, the evidence to support this claim is lacking. For
example, previous studies have shown that completely effector-
less murine anti-A antibodies are capable of reducing plaque
load in mice, while reducing the risks associated with vascular
damage (Carty et al., 2006; Wilcock et al., 2006). Nevertheless,
these studies did not directly test the ability of these antibodies to
promote microglial engulfment of A. Also, these studies were
conducted with antibodies that only bind to the less toxic
C-terminal region of A1–40. Ideally, an anti-A immunother-
apy approachwould combine the essential A binding properties
to maximize efficacy with the appropriate immune modulation
to limit safety findings.
We show that anti-A antibody effector function can bemod-
ulated to maintain A engulfment properties, while limiting ac-
tivation of microglia that may ultimately be deleterious to the
vascular and nervous systems. Furthermore, targeting a unique
epitope on A has allowed us to identify an antibody that binds
multiple forms of A, including oligomeric forms, while inhibit-
ing aggregation and promoting disaggregation of A. Together,
the reduced effector function of MABT, a humanized anti-A
IgG4 antibody, and its unique A binding profile exclusively po-
sition this anti-A immunotherapy candidate to test both mech-
anisms of efficacy and safety in the clinic. Indeed, phase I data
presented in this report are consistent with this hypothesis, show-
ing that, at dose levels and exposure 10-fold compared with
other anti-AmAbs on human IgG1 backbones (Salloway et al.,
2009; Ostrowitzki et al., 2012), MABT showed no signs of vaso-
genic edema. Interestingly, however, solanezumab is also on a
human IgG1 backbone, but has not shown the same level of va-
sogenic edema as other human IgG1 anti-A antibodies (Carlson
et al., 2011). This is likely because solanezumab does not recog-
nize aggregated A and thus does not bind vascular amyloid and
elicit an immune response causing disruption of the blood–brain
barrier.
Having identified an anti-A antibody with in vivo efficacy
and unique binding properties, we set out to investigate the abil-
ity of MABT to inhibit A-mediated cellular toxicity. A recent
study has demonstrated that the two adjacent histidines at posi-
tion 13 and 14 of A are necessary for cellmembrane binding and
uptake (Poduslo et al., 2010). These histidine residues overlap
with the epitope of MABT, thus predicting the results of A
cellular binding studies in which we observe robust inhibition of
A binding to neurons. In addition to blocking A interaction
with neurons, we see that toxicity mediated by A oligomers is
also inhibited; thus, MABT is neuroprotective to toxicity medi-
ated by A.
In the process of evaluating A-mediated cellular toxicity in
mixed neuronal culture systems, which include neurons, micro-
glia, and astrocytes, we observed an accumulation of A after
treatment withMABT in an unidentified cell type not resembling
a neuron. Further investigation identified this cell type as micro-
glial, based on Iba1 staining and confirmed in studies using pu-
rified CX3CR1-GFPmicroglia.Wewere intrigued by these initial
observations, as MABT is an IgG4 antibody, which has reduced
FcR binding properties compared with a wild-type IgG1 and
4
(Figure legend continued.) with 10 M A1–42 oligomers alone or together with 100
g/mlMABTorMABT-IgG1-D265A, in thepresence or absence of 1MSB239063, a p38MAPK-
specific inhibitor. A cytotoxicity assay using the MTT readout was performed after 24 h. The
mean (SEM) of four experiments is shown. Statistical analysis was done using one-way
ANOVA followed by Tukey’s post hoc multiple comparison. E, IgG1 is less effective in reducing
A1–42-mediated proinflammatory release by microglia as measured by TNF levels from
conditioned media of enriched microglia following 24 h of treatment. The mean (SEM) of
three independent experiments is shown. Statistical analysis was done using one-way ANOVA
followed by Tukey’s post hocmultiple comparison.
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may therefore be less effective at promoting A engulfment (for
review, seeNimmerjahn andRavetch, 2006). Thus, to explore the
relative contribution of IgG isotype and associated effector func-
tion to A engulfment bymicroglia, we generated two additional
variants ofMABTwith equal binding affinity to A, but one with
full effector function (MABT-IgG1) and one with no effector
function (MABT-IgG1-D265A). Using these reagents, we ob-
served that MABT-IgG4 was nearly as effective as the IgG1
variant at promoting A engulfment. In contrast, MABT-IgG1-
D265A showed modest-to-little promotion of A engulfment.
These data suggest that effector functionmay be necessary for A
engulfment; however, modest binding to FcRsmay be sufficient
to obtain the desired microglial uptake while limiting activation
and a proinflammatory response. Furthermore, we confirmed
thatMABT could reduce A pathology in vivo using live imaging
in hAPP(V717I)/PS1 transgenic mice to assess plaque dynamics
after dosing.
Unlike FcR binding, neonatal Fc receptor (FcRn) binding is
not substantially different between IgG4, IgG1, and IgG1-D265A.
Although it is notable that altering Fc receptor binding alone is
sufficient to alter ability ofmicroglial engulfment of A, this does
not rule out the possibility that completely effectorless anti-A
antibodies may be efficacious in vivo via a FcRn-mediated mech-
anism. Indeed, previous studies have shown that effectorless an-
tibodies are efficacious in vivo (Carty et al., 2006; Wilcock et al.,
2006); furthermore, an FcRn-driven mechanism of anti-A ac-
tion has been directly investigated, suggesting that A/anti-A
complexes are cleared across the blood–brain barrier via an
Figure 7. MABT phase I clinical study results. A, Phase I clinical study design. B, Actual study population. C, The serum MABT concentration–time profiles following both single (SD phase) or
weekly (MD phase) intravenous administration increased in proportion to dose and were characterized by slow clearance (3 ml  d1  kg1) and a long half-life (18–23 d). D, Increases in
plasma total A1–40and total A1–42 correlatedwellwith serumMABT concentration following single orweekly administration in the SDphase; serumMABTandplasma total A sampleswere
collected just beforeMABT administration through study day 112. In theMDphase, sampleswere collected just beforeMABT administration on day 0, at 1 h and 7 d after each dose and to 119 d after
last dose through study day 140. Serum MABT concentrations were determined using a quantitative ELISA with a limit of detection (LOD) of 0.0225g/ml. Total plasma levels of A1–40 and
A1–42were determined using an electrochemiluminescence assaywith a LOD of 0.01 and 0.125 nM, respectively. A1–42was not detectable in patients given placebo (or at baseline in patients
given MABT) so is not shown.
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FcRn-dependent pathway (Deane et al., 2005). Thus, in addition
to the IgG4-dependent ability of MABT to drive microglial en-
gulfment of A, it is also reasonable to propose thatMABT could
use FcRn to enhance its activity in vivo.
Interestingly, MABT-IgG4 and MABT-IgG1 were both neu-
roprotective; however, the antibody that had no remaining FcR
binding, MABT-IgG1-D265A, was less protective to A-
mediated cellular toxicity. Even if full effector function via FcR
binding plays a role in the ability ofMABT to promotemicroglial
engulfment of A, MABT-IgG1 did not demonstrate better neu-
roprotection and may have even shown a trend toward reduced
efficacy. We therefore hypothesize that the robust effector func-
tion of an anti-A IgG1 antibody, when complexed to A, may
aberrantly initiate or augment a proinflammatory response that
is detrimental for neuronal cell survival.
There is substantial evidence that microglia are robustly acti-
vated in many neurodegenerative diseases, including AD, and
that activation may be either neuroprotective or neurotoxic de-
pending on yet poorly understood factors (for review, see Ranso-
hoff andPerry, 2009). The p38MAPKpathway plays a central role
in the signaling network responsible for the upregulation of pro-
inflammatory cytokines in microglia, such as TNF, and regu-
lates their biosynthesis by multiple mechanisms (Simon et al.,
1985; J. C. Lee et al., 1994; Gallagher et al., 1997; Y. B. Lee et al.,
2000). We therefore assayed for p38MAPK response after A
treatment and found thatMABT-IgG1 with full effector function
produced the greatest activation of p38MAPK in microglia. We
also tested for differential effects on TNF release, a downstream
response to p38MAPK activation; all MABT variants tested re-
duced the release of TNF by microglia; however, this effect was
significantly blunted for MABT-IgG1, which has full effector
function. Although there is a well documented role of p38MAPK
in stress-induced and proinflammatory signaling, there is also
evidence for a supportive function of p38MAPK in A phagocy-
tosis (Doyle et al., 2004) and nonamyloid processing of APP
(Bandyopadhyay et al., 2006). These previous findings may ex-
plain why the low p38MAPK activity measured frommixed neu-
ronal cultures treated with A andMABT appears to be required
for full rescue from toxicity, as the neuroprotective effect of
MABT was significantly reduced in the presence of a p38MAPK
inhibitor. Considering the entirety of these data comparing var-
ious IgG isotypes and subsequent effector function by assaying
neuroprotection and microglial activation, we propose that full
effector function of an anti-A antibody is not necessary for neu-
roprotective effects and is likely deleterious when considering
enhanced microglial activation as measured by p38MAPK activ-
ity and relative TNF release.
MABT (also known as crenezumab), a humanized anti-A
IgG4 effector-reduced antibody, was selected for its in vitro and in
vivo efficacy, including ability to protect neurons from A
oligomer-induced toxicity. MABT was also selected for its ability
to promote microglial engulfment of A without aberrantly ac-
tivating microglia. Based on these preclinical data, we hypothe-
size that MABT would have a reduced risk of vascular-related
findings, which are likely a consequence of an anti-A antibody
binding aggregated A and maintaining full effector function to
elicit a proinflammatory reaction around vascular amyloid. Sup-
ported by these preclinical data, a single and multiple dose, mul-
ticenter, randomized, placebo-controlled, double-blind phase I
study to assess safety, pharmacokinetics, and pharmacodynamics
was conducted in patients with mild-to-moderate AD. Magnetic
resonance imaging results from this study are consistent with the
hypothesis proposed herein, as no patients showed signs of vaso-
genic edema after either single or multiple doses. Moving for-
ward, larger clinical studies are underway to fully test the efficacy
and safety of crenezumab in AD patients.
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